Psilocybin molecule:

Image from PubChem

Psilocybin Clinical Trials


The Efficacy and Tolerability of Psilocybin in Participants With Treatment-Resistant Depression: a Phase 2, Randomized Feasibility Study


To see complete record on clinicaltrials.gov, please visit this link

Id: NCT05029466

Organisation Name: Brain and Cognition Discovery Foundation

Overal Status: Not yet recruiting

Start Date: October 2021

Last Update: September 5, 2021

Lead Sponsor: Brain and Cognition Discovery Foundation

Brief Summary: The purpose of this study is to see if psilocybin, an investigational drug, is safe and well tolerated. Researchers also want to know if psilocybin can improve symptoms of depression. This study will see if psilocybin is safe and well tolerated by tracking changes in suicidal thoughts and behaviour, monitoring if any participants choose to stop participating in the study, and measuring any serious side effects, as well as how long they take to resolve. This study will also see if depression symptoms improve (or worsen) after psilocybin is administered. Additional information about participants' depressive symptoms and side effects will also be measured during the study.

Conditions:
  • Treatment Resistant Depression


Total execution time in seconds: 0.17798185348511